The collaboration combines Insilico's Pharma.AI platforms with Lilly's expertise to discover and advance new therapies. Insilico will utilize its platform to generate candidate compounds, accelerating the development of transformative treatments for urgent patient needs.
Insilico Medicine launches innovative cardiometabolic disease portfolio powered by its proprietary Pharma.AI platform, targeting established and moderate-novelty targets. The portfolio features two novel GLP-1RAs designed for improved safety and pharmacokinetics at low dose to allow multi-pill combinations.
Insilico Medicine has demonstrated the potential of generative biologics to rapidly design peptides targeting GLP1R, a receptor modulated by blockbuster diabetes drugs. The company generated over 5,000 novel peptides within a 72-hour cycle and identified 14 with biological activity.
Insilico Medicine has been named a 2025 BostInno Fire Awards honoree for its groundbreaking achievements in AI-driven drug discovery. The company's lead asset, Rentosertib (ISM001-055), demonstrated potential signs of lung function restoration in idiopathic pulmonary fibrosis patients.
Insilico Medicine will introduce its emerging Cardiometabolic Portfolio and showcase the capabilities of its end-to-end Pharma.AI platform at BIO-Europe 2025. The company's business development team will be available for meetings to pursue strategic collaborations.
Insilico Medicine's Alex Zhavoronkov and Alex Aliper will share their insights on generative AI breakthroughs in healthcare. The company is leveraging AI to accelerate drug discovery, reducing the time from traditional methods by 2.5-4 years.
At the 2025 Fortune Global Forum, Insilico Medicine's CEO Dr. Alex Zhavoronkov will share his vision for a future where generative AI can help humanity live better and longer. The company has advanced its AI algorithm development and built industry collaborations across the Middle East.
Insilico Medicine has released several AI-powered tools, including PandaOmics and Generative Biologics, to accelerate drug discovery. These platforms utilize machine learning and AI models to analyze large datasets and generate novel hypotheses.
Pharma.AI is a comprehensive generative AI-powered drug discovery platform featuring PandaOmics, Generative Biologics, Chemistry42, Science42: DORA, and PreciousGPT. These platforms enhance target and biomarker discovery, biologics engineering, small molecule design, scientific research, and disease modelling.
Insilico Medicine's founder Alex Zhavoronkov, PhD, is named among 100 global leaders driving the future of artificial intelligence. The company has developed breakthrough solutions for novel target discovery and drug development using generative AI.
The partnership enables AI-driven design, antibody development, payload-linker synthesis, and clinical development to accelerate ADC drug discovery and development. The collaboration aims to deliver more effective treatment options for cancer patients worldwide by integrating cutting-edge technology and expertise.
The global market for AI in pharmaceuticals is projected to reach $13.4 billion by 2035, driven by Insilico Medicine's innovative use of generative AI. The company will share its achievements at a satellite forum during BIOHK2025, showcasing significant efficiency boosts compared to traditional methods.
The ARDD conference will unveil the latest advancements in cell simulation, deep aging biomarkers, and cellular aging mechanisms, driving healthy longevity research forward. Insilico Medicine is a pioneer in this field with AI-driven research on aging and longevity.
Insilico Medicine has completed IND-enabling studies for ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders. The drug candidate demonstrated favorable PD/PK profiles and dose-dependent efficacy in motor functions in animal models.
Researchers at Insilico Medicine used AI tools to investigate the connection between IPF and accelerated aging, identifying four key pathways central to both conditions. The study found that patients with severe infections had significantly higher predicted biological ages, suggesting a link between fibrosis and aging.
The Insilico Medicine recent summer updates webinar introduced new features and functional updates to the company's generative AI platform, including Generative Biologics, Chemistry42, PandaOmics, DORA, and PreciousGPT. These updates aim to accelerate drug discovery and advance life sciences research.
Insilico Medicine's latest Pharma.ai updates showcase advancements in Biology42 and Chemistry42, enhancing antibody design and omics data analysis. The company's AI software suite has demonstrated significant efficiency improvements in practical applications, setting a benchmark for AI-driven drug research.
At the upcoming AI for Good Global Summit, Alex Zhavoronkov PhD will discuss the future potential of generative AI. Insilico Medicine's founder and CEO has invented critical technologies in generative AI and reinforcement learning, and his keynote will explore applications in drug discovery and longevity.
Researchers employed advanced molecular modeling and generative AI to design highly selective FGFR2/3 inhibitors, overcoming therapeutic resistance in various cancers. ISM7594 exhibited nanomolar inhibitory activity against FGFR2/3 with over 100-fold selectivity, showing robust antiproliferative effects.
Insilico Medicine secured a position among the Top 100 global corporate institutions for biological sciences and natural sciences publications. The company's remarkable rise was driven by two studies published in Nature Biotechnology, highlighting the transformative potential of AI in providing solutions for unmet medical needs.
The collaboration aims to bridge academia and industry through joint research projects, academic exchange, and hands-on training for students and faculty. The partnership also opens career opportunities for UAEU graduates at Insilico, fostering local talent and supporting the expansion of the UAE's biotechnology sector.
Insilico Medicine has completed the first-in-patient dosing of ISM3412, a novel MAT2A inhibitor with potential as a best-in-class treatment for locally advanced and metastatic solid tumors. The Phase 1 study aims to evaluate safety, tolerability, and preliminary anti-tumor efficacy of ISM3412.
Nach01, a large language model-based foundation model, leverages structural and spatial data for diverse chemical tasks. The model is now available on AWS Marketplace, streamlining access for researchers and pharma companies to build and apply large-scale generative models.
The Phase IIa trial of Rentosertib showed encouraging clinical data, with patients receiving the treatment experiencing significant improvements in lung function compared to placebo. The study also validated the biological mechanism of TNIK inhibition using exploratory biomarkers analyses.
Researchers developed novel ENPP1 inhibitors to modulate the STING pathway and enhance tumor immunity, overcoming challenges faced by direct STING agonists. The top candidate compound ISM5939 demonstrates high selectivity and potency for ENPP1 inhibition, potentiating effects of existing cancer treatments.
Researchers discovered novel small-molecule inhibitors targeting the WDR5-MYC protein-protein interaction, demonstrating improved inhibitory activity compared to reference compounds. The lead compound, 9c-1, showed a 35-fold enhancement in activity and sub-micromolar binding affinity.
Insilico Medicine is launching a pilot project in the UAE to discover a novel drug candidate for oncology therapeutics using its proprietary Pharma.AI platform. The project aims to accelerate traditional drug discovery timelines and leverage local talent to create world-class therapeutics.
Insilico Medicine will present detailed Phase IIa data on rentosertib, a novel TNIK inhibitor developed using generative AI, for the treatment of idiopathic pulmonary fibrosis (IPF). The company has previously demonstrated encouraging results from its Phase IIa study, showing favorable safety and tolerability across all dose levels.
Insilico Medicine's Pharma.AI Day 2025 will showcase the latest AI breakthroughs and updates, including precision target discovery engine PandaOmics and generative biologics platform Generative Biologics. The company aims to accelerate drug discovery and advance life sciences research with its proprietary platform.
Insilico Medicine is presenting significant achievements in cancer therapy and immunology, including AI-powered discovery of potential therapies and novel solutions for unmet needs. The company's Pharma.AI platform has received IND clearance for 10 molecules, with promising results in Phase 2a clinical studies.
Insilico Medicine is a pioneer in generative AI-driven healthcare, showcasing its Pharma.AI platform and pipeline portfolio featuring IND clearance molecules. The company will share insights at Abu Dhabi Global Health Week panel discussions, focusing on longevity and precision health.
Insilico Medicine has secured a $110 million Series E financing to accelerate the advancement of its AI-driven drug discovery pipeline and platform developments. The funds will focus on refining AI models and algorithms, as well as advancing clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment.
Rentosertib, a breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF), has been granted an official generic name by the USAN Council. The drug's development was accelerated using generative AI, identifying TNIK as a promising target and designing small-molecule compounds in just 18 months.
Insilico Medicine has deployed the first bipedal humanoid AI scientist, Supervisor, to aid in data acquisition and generation for training embodied AI systems. The humanoid will assist with lab tours, telepresence, tracking, and supervision, bridging the gap between human-free fully-autonomous robotics facilities.
The collaboration combines Insilico's Pharma.AI platform with Tenacia's expertise in CNS biology and clinical development. By leveraging generative AI, the partnership seeks to expand therapeutic options and enhance outcomes for patients worldwide. Recent successes by Insilico include the nomination of ISM8969, a BBB penetrable NLRP3 i...
Insilico Medicine has discovered a potent and selective CDK12/13 dual inhibitor, compound 12b, using AI-powered platforms. The compound shows significant efficacy in breast cancer and AML models without inducing side effects, paving the way for further therapeutic development.
InSilico Medicine achieved a preclinical milestone in its collaboration with Therasid Bioscience, optimizing AI-driven compounds targeting MASH. The team synthesized and tested approximately 40 molecules in just 4 months, identifying candidate compounds with highly satisfactory properties.
A groundbreaking study using AI-driven robotics laboratory identifies Rentosertib, a potent TNIK inhibitor, as a highly effective senomorphic agent capable of reducing aging-related markers. The study reveals TNIK inhibition alleviates key signaling pathways implicated in senescence and fibrosis.
The collaboration aims to accelerate antibody discovery and development using Harbour BioMed's technology platform and Insilico's AI expertise. The companies will develop next-generation AI-powered antibodies for immunology, oncology, and neuroscience, aiming to deliver innovative therapies with enhanced specificity, efficacy, and safety.
Insilico Medicine has nominated 22 developmental candidates, with 10 progressing to human clinical stage, demonstrating efficient drug discovery using generative AI. The company's platform reduces developmental times, cost, and resource allocation, setting a new standard for the industry.
Insilico Medicine has developed a highly selective FGFR2/3 dual inhibitor, which maintains efficacy against resistance mutations and demonstrates a more favorable safety profile compared to existing FGFR inhibitors. The compound showed robust antitumor efficacy in gastric cancer mouse models.
Insilico Medicine has successfully dosed the first patient in its global Phase I clinical trial of ISM6331, a potent pan-TEAD inhibitor. The treatment demonstrates superior efficacy and safety in preclinical studies, with potential synergistic anti-tumor effects and overcoming drug resistance.
Insilico Medicine's AI-driven platform, PandaOmics, identifies two new therapeutic targets and a repurposed FDA-approved drug for treating endometriosis. The study reveals guanylate-binding protein 2 (GBP2) and hematopoietic cell kinase (HCK) as key proteins involved in the disease mechanism.
The Menarini Group and Insilico Medicine have entered into an exclusive licensing agreement for a preclinical small molecule targeting solid tumor cancers. The asset has demonstrated broad anti-tumor activity in selected cancers, offering new treatment options for cancer patients with high unmet needs.
Positive Phase 1 trial results suggest ISM5411's gut-restrictive property and favorable pharmacokinetic profile, validating its potential for treating inflammatory bowel disease. Insilico Medicine expects to initiate a Phase 2 proof-of-concept study in active ulcerative colitis patients.
ISM1745, a potentially best-in-class small molecule inhibitor, has been nominated as a preclinical candidate for the treatment of MTAP-deleted cancers. It targets Protein arginine methyltransferase 5 (PRMT5), which is elevated in various cancers and correlates with poor prognostic outcomes.
The study uses generative AI to identify and optimize potent and selective HPK1 inhibitors for immunotherapy. The results show a relatively balanced candidate compound with adequate in vitro ADME, in vivo PK properties, good oral bioavailability, and robust in vivo efficacy in various cancer models.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
Scientists at Insilico Medicine developed a novel gut-restricted PHD inhibitor using generative chemistry engine Chemistry42, promising to repair intestinal mucosal barriers and regulate immune responses in IBD. The compound, ISM5411, demonstrated significant anti-colitis activity without systemic side effects.
Insilico Medicine has nominated ISM8969, an orally available NLRP3 inhibitor, as a potential treatment for various inflammatory diseases. The compound has shown promising results in preclinical evaluation studies, including balanced druggability and efficacy against inflammation.